Join Growin Stock Community!

中裕4147.TW Overview

TW StockBiotech. & Medical
(No presentation for 4147)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

中裕（4147）Overall Performance

中裕（4147）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

中裕（4147） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

中裕（4147）Key Information

中裕（4147）Profile

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes various drugs for the treatment and prevention of infectious diseases. The company develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase III clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which completed Phase I clinical trials for treating HIV infections; and TMB-380, a neutralizing HIV-1 antibody. The company was incorporated in 2007 and is headquartered in Taipei, Taiwan.

中裕（4147）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
37.19%
Net Margin
-36.18%
Revenue Growth (YoY)
-2.47%
Profit Growth (YoY)
-16.55%
3-Year Revenue Growth
15.21%
3-Year Profit Growth
19.18%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
37.19%
Net Margin
-36.18%
Revenue Growth (YoY)
-2.47%
Profit Growth (YoY)
-16.55%
3-Year Revenue Growth
15.21%
3-Year Profit Growth
19.18%
default symbol

4147

中裕

50.60D

-3.36%

(-0.03)

  • When is 4147's latest earnings report released?

    The most recent financial report for 中裕 (4147) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4147's short-term business performance and financial health. For the latest updates on 4147's earnings releases, visit this page regularly.

  • What is the operating profit of 4147?

    According to the latest financial report, 中裕 (4147) reported an Operating Profit of -27.68M with an Operating Margin of -18.74% this period, representing a growth of 39.06% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 4147's revenue growth?

    In the latest financial report, 中裕 (4147) announced revenue of 147.67M, with a Year-Over-Year growth rate of 6.62%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 4147 have?

    At the end of the period, 中裕 (4147) held Total Cash and Cash Equivalents of 839.47M, accounting for 0.17 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 4147 go with three margins increasing?

    In the latest report, 中裕 (4147) did not achieve the “three margins increasing” benchmark, with a gross margin of 38.87%%, operating margin of -18.74%%, and net margin of -9.47%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4147's profit trajectory and future growth potential.

  • Is 4147's EPS continuing to grow?

    According to the past four quarterly reports, 中裕 (4147)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.05. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 4147?

    中裕 (4147)'s Free Cash Flow (FCF) for the period is 9.29M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 82.68% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.